AB0743 Biomarkers in systemic sclerosis: a 23-plex cytokine/chemokine analysis

Autor: C. Perricone, G. Cafaro, R. Ilenia, S. Calvacchi, E. Marcucci, S. Cipriani, O. Bistoni, R. Gerli, E. Bartoloni Bocci
Rok vydání: 2022
Předmět:
Zdroj: Annals of the Rheumatic Diseases. 81:1497.1-1497
ISSN: 1468-2060
0003-4967
DOI: 10.1136/annrheumdis-2022-eular.5061
Popis: BackgroundSystemic Sclerosis (SSc) is a rare inflammatory disease of unknown etiology associated with multi-organ involvement. Biomarkers remain urgently needed as tools for differential diagnosis, prognosis, disease progression, and as therapeutic response predictors in SSc. Ideally, for widespread utility, biomarkers should be easy to sample and analyse.ObjectivesWe aimed at evaluating potentially pathogenic circulating key cytokines/chemokines in a monocentric cohort of SSc patients.MethodsSera were drawn from SSc patients and 23 cytokines/chemokines (CCL2/MCP-1, IP-10/CXCL10, Flt3 Ligand, IFNa2, IL6, IL7, IL12, IL13, IL15, IL17A, TNFa, IL-1Ra, CXCL13, IL21, IL23, IL33, TSLP, IL-2RA, IL1RII, TNFRII, BAFF, CCL19/MIP-3B 66, MMP-8) were quantified using Luminex multiplex immunoassay (BioRad-BioPlex 200 System-Lumine x-Map technology R&D Systems, USA) following the manufacturer’s instructions and customized procedures. Data were acquired using Bioplex manager v 6.1. P value ≤ 0.05 was considered to be significant. Data were analyzed using GraphPad Prism V.8 (GraphPad Software, Inc.) software.ResultsClinical and demographic features of 17 SSc (5 dcSSc, 12 lcSSc) patients are reported in Table 1. Mean±SD age was 55±14.68 years, mean±SD disease duration was 89.47±95.34 months. We found that MCP-1 levels inversely correlated with PAPs (r=-0.55, P=0.03) and IP10 with anti-Scl70 (r=-0.561, P=0.004), Figure 1. No other associations were foundTable 1.N%Sex2M/15F11.8/88.32Age (years, mean±SD)55±14.68Disease duration (months, mean±SD)89.47±95.34Cigarette smoke847Raynaud’s phenomenon17100Skin thickening1482.4Ulcers211.8Rodnan’s Skin Score (mean±SD)5.9±6.6Articular involvement211.8Heart involvement00Paps max (mmhg, mean±SD)28.3±5.9Pulmonary involvement529.4DLCO min (%, mean±SD)90.24±21.2Gastrointestinal involvement317.6ANA17100Rheumatoid factor423.5Anti-Scl70 (U/ml, mean±SD)33.2±59.3Anti-CENP(U/ml, mean±SD)55.9±48.9Anti-SSA211.8Anti-SSB15.9Anti-Sm15.9Anti-RNP15.9Elevated Blood Pressure423.5Obesity15.8Any DMARD529.4ConclusionWe confirm a potential pathogenic role for MCP-1 in SSc. The -2518 promotor polymorphism in the MCP-1 gene has been already associated with disease susceptibility and an increased expression of the molecule both in peripheral blood and in the skin has been described. Intriguingly, MCP-1 seems to drive skin fibrosis while the role played in pulmonary involvement is more controversial. Indeed, similarly to our results, Scala et al. found an inverse correlation between pulmonary fibrosis and MCP-1 from T cell lines (1). At the same extent, the observation that IP-10 has an inverse correlation with anti-Scl70 levels is not novel and the usage of this chemokine as a marker of lcSSc has been already suggested. In this view, Zhu et al. found that Scl-70 negative patients have a higher expression of IP-10 than Scl-70 positive (1,878 (2,964) ng/L vs 1,030 (2,196.6) ng/L, PReferences[1]Scala et al. Clin Exp Immunol 2004[2]Beijing Da Xue Xue Bao Yi Xue Ban. 2019Figure 1.Disclosure of InterestsNone declared
Databáze: OpenAIRE
Externí odkaz: